(Arg) 9 (Synonyms: Nona-L-arginine; Peptide R9)

Art. -Nr.: HY-P0133: Data Sheet Handling Instructions
FAQs
Technical Support

(Arg)9 (Nona-L-arginine) is a cell-penetrating peptide (CPP) made up of 9 arginine residues, which is an inhibitor of serine endoprotease Furin. (Arg)9 has neuroprotective property, exhibits neuroprotective activity with an IC₅₀ of 0.78 μM in the glutamic acid model.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form ((Arg)9 acetate) usually boasts enhanced water solubility and stability.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

(Arg) 9 Chemische Struktur

CAS. Nr. : 143413-47-2

Größe		Verfügbarkeit
MOQ		Minimum order quantity
50 mg		Angebot einholen
100 mg		Angebot einholen
250 mg		Angebot einholen
Other size		Angebot einholen

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of (Arg) 9:

(Arg)9 TFA (Arg)9 acetate

Other Forms of (Arg) 9:

(Arg)9 TFA In-stock
(Arg)9 acetate In-stock

1 Publications Citing Use of MCE (Arg) 9

•In Vitro Cell Dev Biol-Pl. 06 January 2022.

Spezialitätsempfehlungen

•Related Small Molecules:

•Related Proteins:

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

IC₅₀ & Target

IC50: 0.78 μM (neuroprotection)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 3 Compound: p-03	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
A549	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
BEAS-2B	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
BEAS-2B	IC₅₀	>100 3 Compound: p-03	Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
A549	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
HepG2	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
HepG2	IC₅₀	>100 3 Compound: p-03	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
L02	IC₅₀	>100 3 Compound: p-03	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
BEAS-2B	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
L02	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
HepG2	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]
L02	IC₅₀	> 100 3 Compound: p-03	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 24 hrs by CCK-8 assay	[PMID: 35452935]

In Vitro

(Arg)9 (Nona-L-arginine; 5-10 μM) provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC₅₀=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC₅₀=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC₅₀=6 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague-Dawley ratspermanent middle cerebral artery stroke model) shows neuroprotective effects and reduces infarct volume^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model^[2]
Dosage:	1 μM/kg (600 μL)
Administration:	Intravenous injection; once, over 5 minutes
Result:	Reduced significantiy 20% in infarct volume.

Klinische Studie

Molekulargewicht

1423.69

Formel

C₅₄H₁₁₀N₃₆O₁₀

CAS. Nr.

143413-47-2

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg

Sequence Shortening

RRRRRRRRR

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Cameron A, et al. Polyarginines are potent furin inhibitors. J Biol Chem. 2000 Nov 24;275(47):36741-9. [Content Brief]

[2]. Meloni BP, et, al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81. [Content Brief]

[3]. Meloni BP, et, al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004. [Content Brief]

(Arg) 9 Related Classifications

Neurological Disease

Molaritätsrechner
Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Diese Gleichung wird häufig abgekürzt als: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(Arg) 9143413-47-2Nona-L-argininePeptide R9Peptide R 9Peptide R-9Ser/Thr ProteaseSerine proteasesSerine endopeptidasesThreonine proteasescell-penetrating peptideneuroprotective propertyarginineinfarct volumeInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Produktname

Requested Quantity *

Name des Antragstellers *

Anrede

E-Mail-Addresse *

Telefonnummer *

Department

Name der Organisation *

City

Bundesland

Country or Region *

Bemerkungen

Produktname

Lot #

Name des Antragstellers *

E-Mail-Addresse *

Telefonnummer

Department *